Abstract
Objective:
The purpose of this article is to review cancer- and therapy-specific tumor response assessment criteria used in clinical trials and in practice, with illustrative case examples, and to discuss future directions toward "personalized" tumor response assessment.
Conclusion:
Although Response Evaluation Criteria in Solid Tumors will remain as the primary generalized criteria for response assessment, newer cancer- and therapy-specific criteria will play an important role in providing state-of-the-art response assessment of tumor following molecular targeted therapy and will contribute to personalized cancer care in the era of molecular medicine.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Angiogenesis Inhibitors / therapeutic use
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / pathology*
-
Carcinoma, Renal Cell / drug therapy*
-
Carcinoma, Renal Cell / pathology*
-
Clinical Trials as Topic
-
Diagnostic Imaging*
-
Disease Progression
-
Humans
-
Immunotherapy / methods
-
Kidney Neoplasms / drug therapy*
-
Kidney Neoplasms / pathology*
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / pathology*
-
Melanoma / drug therapy*
-
Melanoma / pathology*
-
Molecular Targeted Therapy / trends*
-
Outcome Assessment, Health Care / standards*
-
Precision Medicine*
-
Predictive Value of Tests
-
Prognosis